Benjamin F. Edwards & Company Inc. Boosts Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Benjamin F. Edwards & Company Inc. lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 145.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,977 shares of the company’s stock after buying an additional 18,347 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Kenvue were worth $667,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. raised its stake in Kenvue by 59.4% in the fourth quarter. First Horizon Advisors Inc. now owns 18,748 shares of the company’s stock valued at $404,000 after buying an additional 6,983 shares in the last quarter. Swiss National Bank boosted its holdings in Kenvue by 9.4% in the fourth quarter. Swiss National Bank now owns 5,389,046 shares of the company’s stock valued at $116,026,000 after purchasing an additional 461,600 shares in the last quarter. JFG Wealth Management LLC acquired a new stake in Kenvue during the fourth quarter worth approximately $219,000. First Trust Direct Indexing L.P. purchased a new stake in shares of Kenvue during the 4th quarter worth approximately $408,000. Finally, Victory Capital Management Inc. lifted its position in shares of Kenvue by 0.6% during the 4th quarter. Victory Capital Management Inc. now owns 526,301 shares of the company’s stock worth $11,331,000 after buying an additional 3,014 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KVUE. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Royal Bank of Canada reduced their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. The Goldman Sachs Group started coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Sanford C. Bernstein initiated coverage on shares of Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. Finally, William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Price Performance

KVUE opened at $20.08 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80. The business has a 50 day simple moving average of $19.85 and a 200-day simple moving average of $20.11.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, research analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 3.98%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.